Introduction and Objective: The UC Diabetes Prevention Program (UC DPP) was implemented across all 10 UC campuses in 2018. We conducted qualitative interviews with UC DPP implementation partners (IP) in 2021 (“Wave 1”) and a second set of qualitative interviews at seven years follow-up in 2025 (“Wave 2”) to assess shifts in themes related to UC DPP maintenance over time. Methods: We used a semi-structured interview guide assessing RE-AIM domains to conduct 30 in-depth interviews with IP between March-May 2025. Interviews were recorded, transcribed, and analyzed using rapid qualitative analysis, a widely accepted qualitative method. We compared themes from both waves of interviews, categorizing them as continuous, evolving, and novel. Results: We observed continuity for all seven main Wave 1 themes across Wave 2, suggesting that factors, such as funding and staffing, are critical for program implementation and maintenance at all stages. Some themes evolved over time, including curriculum modifications to emphasize healthy lifestyle behaviors and tailoring for diverse groups. Novel subthemes also emerged in Wave 2, including 1) Enrollment (e.g., programmatic changes increase reach); 2) Use of an Evidence Based Curriculum (e.g., social drivers of health affect retention and the value of community); 3) Funding (e.g., UC DPP as cost saving); 4) Linkages and Resources (e.g., provision of resources to address social drivers of health). Wave 2 IP also highlighted an 8th main theme, Impacts, with two subthemes (e.g., UC DPP improves participant-level health and positively impacts the UC system). Conclusion: Over 7 years of follow-up, we found elements of continuity in all implementation themes, along with the emergence of novel themes tied to maintenance success. Barriers and facilitators to program implementation and maintenance can overlap; there are also important shifts over time as programs transition from implementation to maintenance that warrant attention. Disclosure J. Cushing: None. T.B. Loeb: None. A.M. Smith-Clapham: None. O. Duru: Consultant; Current; Boehringer Ingelheim International GmbH. C. Mangione: None. S. Soetenga: None. K.L. Shedd: None. U.R. Chung: None. W. Slusser: Stock/Shareholder; Current; Amgen Inc., Merck & Co., Inc., Novo Nordisk A/S. A. Hamilton: None. T. Moin: None. Funding NIH/NIDDK (1R01DK124503)
Cushing et al. (Fri,) studied this question.